# The role of Esx-3 in mediating drug resistance > **NIH NIH R01** · SEATTLE CHILDREN'S HOSPITAL · 2021 · $464,998 ## Abstract Tuberculosis is a major cause of human suffering worldwide, with 1.8 million deaths and 10.4 million new cases in 2015. Although effective drug regimens for the treatment of TB exist, they are lengthy and involve multiple antibiotics to achieve sterilization and prevent relapse. The current treatment for TB is complex and lengthy requiring a minimum of six months with four drugs for the simplest of cases. It is not clear why drug therapy is so prolonged, although several theories relating to the physiological state of the bacteria have been proposed; these include the existence of drug-tolerant populations during infection, the presence of non-replicating (or slowly- replicating bacilli) and the lack of drug penetration to the sites of infection. Much recent effort has been expended in phenotypic screening to identify new molecular series for drug discovery and development; alongside which a chemical genomics approach has been taken to find novel drug targets using hit compounds identified in these screens. We are interested both in developing novel drugs and in understanding how such drugs work. We have identified a common mechanism of resistance to several, chemically-unrelated series in M. tuberculosis which involves mutation in a type VII secretion system (T7SS). We have identified compounds with interesting biological activities and which appear to work via similar mechanisms, or at least resistance is engendered by the same mechanism. Our proposal aims to determine the mode of action of these compounds. We propose that mode of action is via disruption of metal ion homeostasis with additional downstream effects, which would be a novel mechanism for future drug discovery efforts. We have identified mutations in several components of the Esx-3 T7SS (EccA3, EccB3, EccC3 and EccD3) which confer resistance to three compound series. It is unlikely that the Esx-3 system is the cellular target for these compounds, since mutations were found in four different genes, including one cytosolic protein that would not form part of the complex. Therefore it seems likely that resistance arises from a mechanism distinct from loss of compound-target binding. We propose to take a number of approaches combining microbiology, molecular biology and biochemistry to (i) determine the mode of action of compound series (ii) determine how the Esx- 3 T7SS can mediate compound resistance, and (iii) identify and characterize the targets of each series. ## Key facts - **NIH application ID:** 9984947 - **Project number:** 5R01AI129360-04 - **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL - **Principal Investigator:** Tanya Parish - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $464,998 - **Award type:** 5 - **Project period:** 2020-01-01 → 2023-08-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9984947 ## Citation > US National Institutes of Health, RePORTER application 9984947, The role of Esx-3 in mediating drug resistance (5R01AI129360-04). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9984947. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*